New leadership brings biotech and large pharma experience to lead
commercialization phase for a leading AIDS/HIV R&D company
BALTIMORE, Jan. 28 /PRNewswire/ -- Profectus BioSciences Inc., a biotechnology company that develops preventative and therapeutic technologies to reduce the morbidity and mortality of viral diseases, today announced that its board of directors has appointed Shawn Patrick O'Brien as the company's president and chief executive officer. O'Brien will also serve as a director of the company. The appointment comes as Profectus BioSciences enters the commercialization phase of operations.
To date, Profectus BioSciences has a unique relationship with the Institute of Human Virology (http://www.IHV.org), along with other academic and government institutions to gain access to breakthrough technologies focused on the treatment and prevention of AIDS/HIV. Currently, the Company has five technology platforms and two commercialization partners to progress the development of its AIDS vaccine for human and veterinary use. The Company plans to work with other commercialization partners to progress the other four promising technology platforms in the treatment of AIDS/HIV.
O'Brien has extensive global experience in business development, sales, licensing, and R&D at biotech and large pharma companies. He comes to Profectus BioSciences from Solstice Neurosciences Inc., where he served as president and chief executive officer since 2004. During his tenure at Solstice, O'Brien increased key sales by 90 percent, opened the EU market with new partners and patents, addressed unsettled patent issues and expanded the clinical development program to include six investigational new drugs (INDs).
Previously, O'Brien worked with AstraZeneca USA as vice president of
commercial operations for emerging brands, and as vice president and
therapy area leader for the respiratory and infla
|SOURCE Profectus BioSciences Inc.|
Copyright©2008 PR Newswire.
All rights reserved